Harpoon Therapeutics has bagged fast track designation for HPN217 from the US Food and Drug Administration (FDA) for the treatment of certain patient population with relapsed, refractory multiple myeloma (RRMM).

HPN217 is a B-cell maturation antigen (BCMA) targeting Tri-specific T cell Activating Construct (TriTAC). Its fast track designation is for relapsed, refractory multiple myeloma patients who had gone through at least four lines of therapy.

Presently, a phase 1/2 clinical trial for HPN217 is going on in the relapsed, refractory multiple myeloma patient population.

Julie Eastland – President and CEO of Harpoon Therapeutics said: “We are pleased that HPN217 has received FDA Fast Track designation because it highlights the serious unmet medical need for patients with relapsed, refractory multiple myeloma who received multiple lines of therapy.

“We are focused on selecting an initial dose to study in the expansion phase of the ongoing Phase 1/2 clinical trial in the first half of this year as we progress HPN217 forward as an innovative new treatment option for these patients.”

Harpoon Therapeutics has a licensing agreement for HPN217 in place with AbbVie along with an option to advance the cancer drug candidate and expand their existing discovery collaboration. As per the terms of the licensing deal, AbbVie can exercise its option to license HPN217 after wrapping up the ongoing phase 1/2 clinical trial.

  AbbVie, Harpoon Therapeutics, HPN217, Julie Eastland, Multiple myeloma, US FDA, US Food and Drug Administration, USA